ライフサイエンスコーパス: ISS

1 ISS adopts a stable structure consisting of conserved UG

2 ISS consists of an ingestible event marker (IEM), a micr

3 ISS could detect accurately the ingestion of two IEM-ECM

4 ISS DNA induces intestinal expression of IDO-1 but not t

5 ISS Expedition-9 crewmembers attended a 2.5-hour didacti

6 ISS inhibits the Th2 response by rendering lung antigen-

7 ISS is a promising new technology that provides highly r

8 ISS reduced bronchoalveolar lavage and lung levels of TG

9 ISS, CA, and LDH data were simultaneously available in 3

10 responded to intranasally administered 1018 ISS, a representative B class ISS, with strictly TLR9-de

11 evaluating 4 dose levels of a CpG-ODN (1018 ISS) with rituximab in 20 patients with relapsed non-Hod

12 1063 in-flight days) and 21 astronauts on 13 ISS missions (3248 in-flight days), with ground-based da

13 g on 500 (52%) of 963 nights; 12 (75%) of 16 ISS crew members reported using sleep-promoting drugs.

14 We analyzed the intron 7 ISS by mutagenesis, coupled with splicing assays, RNA-af

15 In addition, ISS significantly reduces lung levels of expression of t

16 ocalorimetry, in combination with LEED, AES, ISS, work function, sticking probability measurements, a

17 he lamina propria, which also increase after ISS-oligodeoxynucleotide.

18 evaluated a morpholino (MO) oligomer against ISS-N1 [HSMN2Ex7D(-10,-29)], and delivered this MO to po

19 ISS-N1, an antisense oligonucleotide against ISS-N1 restored exon 7 inclusion in mRNAs derived from t

20 from cardiac uncoupling and covariates (age, ISS, AIS Head Score, total transfusion requirements) was

21 n the non-TGC group when controlled for age, ISS, obesity, and diabetes (P<0.01).

22 used 82 (77%) of these infections and had an ISS calculated.

23 n 24 (0.4%) of 5,665 trauma patients with an ISS of 0-19, as compared with six (5.0%) of 122 patients

24 ared with six (5.0%) of 122 patients with an ISS of 40 or higher.

25 ism of injury, hypotension on admission, and ISS (< or =25 and >25).

26 On the basis of AES and ISS measurements, it was determined that Ca grows mainly

27 C mixtures was further enhanced by CD40L and ISS-ODN treatment.

28 H), EMC92, and UAMS70 (GEP classifiers), and ISS.

29 ect seen on the DMSP/OLS, SNPP/VIIRS-DNB and ISS is not only instrumental, but in fact represents a r

30 on performing surgical exploration, PVL, and ISS results in a marked and rapid hypertrophy of functio

31 prevalent not only during space shuttle and ISS missions, but also throughout a 3 month preflight tr

32 Analysis of authentic ISS water samples using the ETV-AQM showed that DMSD cou

33 Time-averaged ISS (ISSave) in the thoracic aorta also increased in the

34 A CpG-B ISS-ODN increased CD80/CD86 expression by PDCs, but resu

35 Baseline ISS levels of PGE(2) were higher in asthmatics as compar

36 th DTP3 coverage of 65% or less at baseline, ISS spending per surviving child had a significant posit

37 Because ISS funding seems to have no effect in countries with ba

38 d tomographic volumetry was performed before ISS and before completion surgery.

39 Thus, inhibition by ISS of allergic responses can be explained by two novel

40 nomic and physiological features selected by ISS conditions do not appear to be directly relevant to

41 The CpG-C ISS-ODN also stimulated IL-12 release (unlike AT-2 SIV)

42 In contrast, a CpG-C ISS-ODN and aldrithiol-2-inactivated (AT-2) SIV induced

43 We have shown that the CpG-C ISS-ODN C274 stimulates macaque blood dendritic cells (D

44 fected macaques, revealing a promising CpG-C ISS-ODN-driven DC activation strategy that boosts immune

45 tivities, supporting the potential for CpG-C ISS-ODNs to boost immune function to enhance anti-HIV va

46 Post-challenge ISS levels of PGE(2) compared to baseline significantly

47 inistered 1018 ISS, a representative B class ISS, with strictly TLR9-dependent toxicity, including lu

48 ho were not identified by existing clinical (ISS stage III) and tumor (GEP-70) criteria as high risk.

49 We conducted ISS by monitoring patients with influenza-like illness (

50 structure of the phylogenetically conserved ISS stem loop.

51 In contrast, ISS inhalation has unexplained toxicity in rodents, whic

52 ncrease in mean ISS between cohorts (pre-DCR ISS = 23 vs DCR ISS = 27; P < .05) and a marked shift in

53 ISS between cohorts (pre-DCR ISS = 23 vs DCR ISS = 27; P < .05) and a marked shift in injury patterns

54 activation of TLR9 by immunostimulatory DNA (ISS-ODN), induces a prominent Th2-biased immune response

55 whether immunostimulatory sequences of DNA (ISS) can reverse established airway remodeling, mice tha

56 all models, but the augmented TMPM dominated ISS by every measure [ROCTMPM = 0.925(0.921-0.928), ROCI

57 ides targeting either upstream or downstream ISS elements increased alpha-exon inclusion from 10% up

58 nstrated the feasibility of integrating EIS, ISS, and IVUS for a catheter-based approach to assess me

59 The EMC92-ISS classification is a novel prognostic tool, based on

60 g risk classifications showed that the EMC92-ISS combination is the strongest predictor for overall s

61 itor of many of the activities described for ISS, and this may impact the use of ISS in disease state

62 The optimal cut-off for ISS was 33, with sensitivity of 60.0%, specificity of 80

63 GAVI ISS significantly increased the difference between offic

64 d from surveys at a rate of US$20 each, GAVI ISS payments are estimated at $150 million (115 million

65 dependent variable and the presence of GAVI ISS as the independent variable, controlling for country

66 Up to 2006, in 51 countries receiving GAVI ISS payments, 7.4 million (5.7 million to 9.2 million) a

67 in all but the most severely injured group (ISS > 40).

68 ds (CICs), which contain multiple heptameric ISS connected by non-nucleoside spacers in both linear a

69 3) triggered more prompt transfer, but high ISS was underappreciated and did not result in a prompt

70 In the high-ISS category (51-75) (n = 75; 4.6%), time to operation w

71 TBI patients had normal neuroimaging, higher ISS, and comparable LOS to TBI-negative patients.

72 Mortality was associated with higher ISS and AIS scores.

73 he Lyon center received patients with higher ISS, lower Glasgow Coma Score (GCS), and lower systolic

74 ociated with higher APACHE II scores, higher ISSs, and previous carbapenem antibiotics in comparison

75 If ISS expenditure only is assessed, the estimated cost per

76 line coverage of 65% or less is US$14 and if ISS and non-ISS expenditures are included the cost per c

77 IDO-1 by a TLR-9 agonist, immunostimulatory (ISS) DNA, critically contributes to its colitis limiting

78 ty (mostly 0G) and artificial produced 1G in ISS (international space station) on mouse bone mass.

79 line with higher pro-inflammatory LTE(4) in ISS and the highest logLTE(4) /logPGE(2) ratio.

80 ognosis and chemotherapy sensitivity (eg, in ISS stage I, one cluster was characterized by increased

81 On the other hand, microgravity in ISS significantly induced the loss of bone mass on humer

82 ntly more sensitive to ethanol than those in ISS neurons.

83 ormal range); R-ISS III (n = 295), including ISS stage III (serum beta2-microglobulin level > 5.5 mg/

84 : revised ISS (R-ISS) I (n = 871), including ISS stage I (serum beta2-microglobulin level < 3.5 mg/L

85 ding patients whose limb fractures increased ISS above 15, the group decreased to 63 patients (20.8%)

86 sputum of allergic humans exposed to inhaled ISS demonstrated induction of IFN-inducible genes but mi

87 ity of patients (74%) were severely injured (ISS > 15), and 80% died within 24 hours of admission.

88 Score (ISS) to classify 84 severely injured (ISS > or =9), 309 non-severely injured (ISS 1-8), and 18

89 red (ISS > or =9), 309 non-severely injured (ISS 1-8), and 189 uninjured (ISS 0) pregnant women and c

90 ith those of 6 patients with minor injuries (ISS </= 4).

91 group, sex, Revised Trauma Score, and injury ISS, ICP monitoring was associated with a reduction in m

92 Silencing of exon IIIc splicing by ISE/ISS-3 was shown to require a branch point sequence (BPS)

93 IIIb; hence, we have termed this element ISE/ISS-3 (for "intronic splicing enhancer-intronic splicing

94 gulated by the auxiliary RNA cis-element ISE/ISS-3 that promotes splicing of exon IIIb and silencing

95 ) binds the FGFR-2 auxiliary cis-element ISE/ISS-3, located in the intron between exon IIIb and IIIc,

96 reviously identified an RNA cis-element, ISE/ISS-3, that enhanced exon IIIb splicing and silenced exo

97 ation of relative functional activity of ISE/ISS-3 mutants using flow cytometric analysis of live cel

98 second step of splicing suggesting that ISE/ISS-3 may block exon IIIc inclusion at this step.

99 splicing regulatory factor that binds to ISE/ISS-3 in a sequence-specific manner.

100 udes it, and association of hnRNP M with ISE/ISS-3 was shown to contribute to this splicing regulator

101 casualties (n = 1054; 61.2%) were in the low-ISS (1-15) bracket in which there was no difference in e

102 ation, and 6.7% (32/480) in ILI with maximum ISS > 2.

103 4%; P <.001, chi(2) test) and a higher mean ISS (25.2 vs 9.7; P <.01, t test).

104 There was a significant increase in mean ISS between cohorts (pre-DCR ISS = 23 vs DCR ISS = 27; P

105 xty-nine patients with severe injuries (mean ISS = 23; hemodynamic instability = 70%; hospital/ICU st

106 ating both groups) and injury severity (mean ISS faculty 10.0; FIEs 9.5).

107 The mean ISS for each S. aureus clone (based on MLST) was compare

108 Patients had a median ISS of 17 with 72% suffering from blunt injury.

109 propose an in silico gene sequencing method (ISS), which predicts phased sequences of intragenic regi

110 Casualties in the mid-ISS bracket (16-50) (n = 583; 33.4%) experienced the sam

111 In this mid-ISS bracket, mortality was lower in the AMR than in the

112 t targets the intronic splicing silencer N1 (ISS-N1), located downstream of the 5' splice site (5'ss)

113 this element intronic splicing silencer N1 (ISS-N1).

114 that we term intronic splicing silencer N2 (ISS-N2).

115 CONCLUSION) The new ISS is simple, based on easy to use variables (Sbeta2M a

116 immunisation services support (ISS) and non-ISS expenditure per surviving child, controlling for inc

117 e of 65% or less is US$14 and if ISS and non-ISS expenditures are included the cost per child is almo

118 tiation of distal GABAA IPSCs in ILS but not ISS mice, and this blockade of GABAB receptor function h

119 The second important action of ISS is inhibition of immunoglobulin E-dependent release

120 Systemic administration of ISS to mice that had already developed established airwa

121 lass II on CD11c(+ )APCs from the airways of ISS-treated mice.

122 s bound by sequence-by-ligation chemistry of ISS.

123 Deletion of ISS-N1 promoted exon 7 inclusion in mRNAs derived from t

124 Here, we demonstrate that airway delivery of ISS before allergen challenge in Th2-primed mice acts in

125 s inhibited, the colitis limiting effects of ISS-oligodeoxynucleotide were abrogated.

126 Confirming the silencer function of ISS-N1, an antisense oligonucleotide against ISS-N1 rest

127 The implementation of ISS enabled characterization of the epidemiology and sea

128 Here, we describe the next iteration of ISS, HybISS, hybridization-based in situ sequencing.

129 oped the first viable genetic mouse model of ISS that spontaneously recapitulates salient phenotypic

130 Underlining the dominant role of ISS-N1 in exon 7 skipping, abrogation of a number of pos

131 e to the differential ethanol sensitivity of ISS and ILS mice.

132 1 pyramidal neurons in hippocampal slices of ISS and ILS mice indicate that ethanol enhances GABAA re

133 The success of ISS funding in countries with baseline DTP3 coverage of

134 ibed for ISS, and this may impact the use of ISS in disease states characterized by elevated IL-10.

135 ial implications of body size and the use of ISS-like CM exercise upon the provision of life-support

136 stimulatory CpG-C oligodeoxyribonucleotides (ISS-ODNs) represent a promising strategy to enhance vacc

137 immunostimulatory oligodeoxyribonucleotides (ISS-ODNs)) is crucial for maximal stimulation of innate

138 363 patients, respectively, were matched on ISS stage and LDH.

139 Crew members on ISS missions obtained significantly less sleep during sp

140 L) and high-risk CA or high LDH level; and R-ISS II (n = 1,894), including all the other possible com

141 d the following three groups: revised ISS (R-ISS) I (n = 871), including ISS stage I (serum beta2-mic

142 ess than the upper limit of normal range); R-ISS III (n = 295), including ISS stage III (serum beta2-

143 months, the 5-year OS rate was 82% in the R-ISS I, 62% in the R-ISS II, and 40% in the R-ISS III gro

144 OS rate was 82% in the R-ISS I, 62% in the R-ISS II, and 40% in the R-ISS III groups; the 5-year PFS

145 ISS I, 62% in the R-ISS II, and 40% in the R-ISS III groups; the 5-year PFS rates were 55%, 36%, and

146 The R-ISS is a simple and powerful prognostic staging system,

147 nt differences in overall complication rate (ISS, 48 [34.5%]; ELM, 37 [27.2%]; P = .19) and mortality

148 LM, 37 [27.2%]; P = .19) and mortality rate (ISS, 10 [7.2%]; ELM, 6 [4.4%]; P = .32) were found.

149 defined the following three groups: revised ISS (R-ISS) I (n = 871), including ISS stage I (serum be

150 P < 0.0001), a higher Injury Severity Score (ISS 5 +/- 8 vs. 9 +/- 11, P < 0.0001), and a higher inci

151 to severely injured [injury severity score (ISS) > 8] adult patients (age >/= 16) presenting alive t

152 years of age and had injury severity score (ISS) >15, were alive on admission and had at least one o

153 imum daily influenza symptom severity score (ISS) >2.

154 16 years and with an Injury Severity Score (ISS) >=10, treated by a Major Trauma Center for the peri

155 ajor trauma patients [Injury Severity Score (ISS) >=9] admitted to 3 Level-I trauma centers in Boston

156 AN group had a higher Injury Severity Score (ISS) (17.5 versus 11.0, P < 0.05), lower Glasgow Coma Sc

157 44 vs. 43 years), and Injury Severity Score (ISS) (26 vs. 25).

158 in 80% with a median injury severity score (ISS) 34 (21, 43).

159 (APACHE II) score or injury severity score (ISS) and previous antibiotic use.

160 from baseline in weekly itch severity score (ISS) at week 12.

161 pared per incremental Injury Severity Score (ISS) bins.

162 as used to derive an illness severity score (ISS) from clinical data, including 30-day mortality, req

163 c brain injury (TBI), Injury Severity Score (ISS) greater than 9, and Glasgow Coma Scale (GCS) score

164 or older and with an Injury Severity Score (ISS) of >= 9.

165 75 males) with a mean injury severity score (ISS) of 24 (range 9-66), from whom blood samples were ac

166 he negative impact of injury severity score (ISS) on mortality (P = 0.071).

167 They used the Injury Severity Score (ISS) to classify 84 severely injured (ISS > or =9), 309

168 The median injury severity score (ISS) was 13 (interquartile range [IQR] 9-22).

169 Higher Injury Severity Score (ISS) was associated with abnormal neuroimaging, longer l

170 Mean age, injury severity score (ISS), and APACHE score were 43 +/- 20 years, 29 +/- 13,

171 Injury severity score (ISS), associated injury, and patient outcome data were g

172 njury scale (AIS) and injury severity score (ISS).

173 al trauma, and higher Injury Severity Score (ISS).

174 7.75 to -2.25), and the itch severity score (ISS)7 (MD -2.15; 95% CI -3.2 to -1.1) does not increase

175 vs. 30 +/- 8 years), Injury Severity Score (ISS; 12 +/- 11 vs. 12 +/- 11), systolic blood pressure i

176 lly injured patients (Injury Severity Score [ISS] >/= 25) at The Royal London Hospital in the hyperac

177 nts (n = 472, average injury severity score [ISS] = 20.2) exhibited elevations in plasma IL33 levels

178 3 years of age) with Injury Severity Scores (ISS) 36.6 +/- 13.9 on days 1 and 7 after trauma and from

179 Injury types and Injury Severity Scores (ISSs), timing and location of death, and initial (24-hou

180 G-containing immunostimulatory DNA sequence (ISS) given before allergen challenge can inhibit T helpe

181 we targeted the intronic silencing sequence (ISS) elements flanking the alternatively spliced alpha-e

182 Immunostimulatory DNA sequences (ISS) containing CpG motifs induce interferon-alpha (IFN-

183 -containing immunostimulatory DNA sequences (ISS), which signal through TLR9, are being developed as

184 In situ sequencing (ISS) method based on padlock probes and rolling circle a

185 n the presence of other variables (age, sex, ISS, Revised Trauma Score, and GCS score) was associated

186 otif of the human intronic splicing silencer ISS-N1, which controls survival of motor neuron exon 7 s

187 directed against an intron splice silencer (ISS) in the survival motor neuron 2 (SMN2) gene alter th

188 We identify an intronic splicing silencer (ISS) adjacent to the M1 branch point that is sufficient

189 treatment to SMN2 intron7-splicing silencer (ISS) improves SMN expression and motor function.

190 ex network of an intronic splicing silencer (ISS), a bipartite exonic splicing silencer (ESS3a/b), an

191 ers (ISEs), and intronic splicing silencers (ISSs), which are typically located near the splice sites

192 identified two intronic splicing silencers (ISSs): one in intron 6 and a recently described one in i

193 rred from Sequence or structural Similarity (ISS)', probably reflecting an error source shift due to

194 sensitivity by utilizing inbred short sleep (ISS) and inbred long sleep (ILS) mouse strains that disp

195 e intrahepatic, small (<7 cm), and solitary (ISS) and those that had extrahepatic extension and were

196 low-energy He+ ion scattering spectroscopy (ISS).

197 vein ligation (PVL), and in situ splitting (ISS) of the liver parenchyma along the falciform ligamen

198 nonsurvivors than does the current standard, ISS.

199 truction of the International Space Station (ISS) and the subsequent extension in mission duration up

200 mission to the International Space Station (ISS) crew members are exposed to a number of stressors t

201 performed in 22 international space station (ISS) crewmembers before and after a ~6-month mission.

202 or assigned to International Space Station (ISS) expeditions between Sept 18, 2006, and March 16, 20

203 The International Space Station (ISS) experiment TRIPLE LUX A, performed in the BIOLAB la

204 launched to the International Space Station (ISS) for 35 days as part of Space-X 12 mission.

205 ironment on the International Space Station (ISS) includes a variety of potential physiologic stresso

206 The International Space Station (ISS) is a unique habitat for humans and microorganisms.

207 launched to the International Space Station (ISS) on Space-X 12 at the Kennedy Space Center (KSC) on

208 ogravity on the International Space Station (ISS) were not protected from muscle atrophy.

209 n-flight on the International Space Station (ISS), and benchmarked its performance off-Earth against

210 d medication in International Space Station (ISS).

211 ance aboard the International Space Station (ISS).

212 lown aboard the International Space Station (ISS).

213 Habitat on the International Space Station (ISS).

214 x months on the International Space Station (ISS).

215 missions to the International Space Station (ISS).

216 -treated boys with idiopathic short stature (ISS) had no loss of bone density but were noted to have

217 vascular ultrasound (IVUS) and shear stress (ISS) provided a new strategy to assess oxLDL-laden lesio

218 Regarding MM, we subclassified ISS stages into clusters based on shared features of tum

219 The Cassini Imaging Science Subsystem (ISS) began observing Saturn in early February 2004.

220 ns by the Cassini Imaging Science Subsystem (ISS) during the first 9 months of Cassini operations at

221 rammetry on Cassini Image Science Subsystem (ISS) images, we measured longitudinal physical forced li

222 s acquired by the Imaging Science Subsystem (ISS), this region is circumscribed by a chain of folded

223 differential cell count and IS supernatant (ISS) levels of prostanoids, PGE(2) , 8-iso-PGE(2) , tetr

224 sanoid levels in induced sputum supernatant (ISS) and urine were extracted for the ANN.

225 e eicosanoids in induced sputum supernatant (ISS).

226 5 to 2004 and immunisation services support (ISS) and non-ISS expenditure per surviving child, contro

227 CI and GAVI's immunisation services support (ISS) might encourage over-reporting.

228 ablished an influenza sentinel surveillance (ISS) system to describe the epidemiology of influenza an

229 Infantile spasms syndrome (ISS) is a catastrophic pediatric epilepsy with motor spa

230 information defined 23 in silico syndromes (ISSs) and was used to test a "phenotype first" approach

231 he accuracy of the Ingestible Sensor System (ISS), a novel technology for directly assessing the inge

232 e superior for International Staging System (ISS) stage 1 disease, when lactate dehydrogenase (LDH) l

233 ith quantified International Staging System (ISS) stage and 70-gene Prognostic Risk Score (GEP-70) sc

234 e status of 1, International Staging System (ISS) stage of 1, and Durie-Salmon stage of IIIA.

235 ) adjusted for International Staging System (ISS) stage.

236 , and subgroup International Staging System (ISS) stages into more prognostically accurate clusters o

237 This new International Staging System (ISS) was validated in the remaining patients and consist

238 e combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by int

239 Here, International Staging System (ISS), fluorescence in situ hybridization (FISH) markers,

240 Overall, these studies demonstrate that ISS can reverse features of airway collagen deposition b

241 These data demonstrate that ISS induce rodent-specific TNF-alpha-dependent toxicity

242 In vitro studies demonstrated that ISS inhibited TGF-beta1 expression by macrophages (RAW 2

243 novel risk classifications demonstrated that ISS is a valuable partner to GEP classifiers and FISH.

244 Knockout mouse experiments demonstrated that ISS-induced toxicity was critically dependent on TNF-alp

245 The ISS also contains a consensus binding site for Rbp1, and

246 The ISS cutoff less than 33 may be useful in the selection p

247 The ISS has served as the standard measure of anatomic injur

248 The ISS system was further validated by demonstrating effect

249 The ISS was found to function independently of its position

250 dult C57BL/6 male mice were flown aboard the ISS for 35 days and returned to Earth alive.

251 ne sequencing runs were performed aboard the ISS over a 6-month period, yielding a total of 276,882 r

252 Aboard the ISS, they completed a 1-hour computer-based Onboard Prof

253 From sequence data collected aboard the ISS, we constructed directed assemblies of the 4.6 Mb E.

254 ysis and microbial identification aboard the ISS.

255 transfer sensor was deployed to acquire the ISS profiles at baseline and post high-fat diet (HD) in

256 ion consisted of time in microgravity at the ISS.

257 neous nuclear ribonucleoprotein A1 binds the ISS apical loop site-specifically and with nanomolar aff

258 thin 38 +/- 4 hours after returning from the ISS, mice were euthanized and brain tissues were collect

259 However, the ISS, age, injury pattern, and length of hospital stay ar

260 nauts that spent six to twelve months in the ISS.

261 before, during and after their stays in the ISS; hereafter, referred to as Preflight, Inflight and P

262 A, performed in the BIOLAB laboratory of the ISS COLUMBUS module, allowed for the first time the dire

263 Simultaneous targeting of the ISS elements had no additive effect, suggesting that spl

264 was demonstrated by similar targeting of the ISS elements of the human hnRNPA1 gene.

265 Here, we report the results of the ISS experiment EXTREMOPHILES, including the analysis of

266 ment microgravity-induced muscle loss on the ISS showed MuRF1 gene expression was not upregulated.

267 need to study new exercise programmes on the ISS that employ high resistance and contractions over a

268 The most frequently used medications on the ISS were for sleep problems, pain, congestion, or allerg

269 The TMPM should replace the ISS as the standard measure of overall injury severity.

270 y of routine sequencing of all subjects, the ISS method proposed here provides a time- and cost-effec

271 experimental therapeutics have targeted the ISS-N1 element of SMN2 pre-mRNA, the development of E1 A

272 survivors from nonsurvivors better than the ISS, but one, the trauma mortality prediction model (TMP

273 58 (35-91), HLISS = 296 (228-357)] than the ISS.

274 We show that the ISS microbial communities are highly similar to those pr

275 cer, we found that Rbp1 and Tra2 bind to the ISS independently through distinct sequences.

276 odels and compare their performance with the ISS using measures of discrimination (C statistic), cali

277 L) genes did not directly correlate with the ISS, being present in the second, fourth, and 10th most

278 ation and calibration when compared with the ISS.

279 und two tandem hnRNP A1/A2 motifs within the ISS that are responsible for its inhibitory character.

280 Furthermore, both binding sites within the ISS-N1 are important for splicing repression and their c

281 data defined elements of function within the ISSs flanking exon IIIb and suggested that silencing of

282 Following 4-day transit from Earth to ISS, video images were acquired on orbit from 16- and 32

283 The Ca here is invisible to ISS, which is attributed to Ca binding to ester groups b

284 the PDC population are cells that respond to ISS by producing either IL-12 or IFN-alpha but not both

285 ppreciable TNF-alpha in vitro in response to ISS stimulation.

286 o inhibit a complex pathological response to ISS, as shown by protection from death after massive sys

287 formation or mRNA transport and translation, ISS-N1 provides a very specific and efficient therapeuti

288 verely injured (ISS 1-8), and 189 uninjured (ISS 0) pregnant women and compared them with pregnant wo

289 f injury and other relevant clinical values, ISS was proportionately predictive of cumulative dose re

290 erence response (5-point decrease) in weekly ISS (P<0.0001) and higher percentages of patients with w

291 Compared with placebo (n=80), mean weekly ISS was reduced from baseline to week 12 by an additiona

292 subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU p

293 of positive cis elements was tolerated when ISS-N1 was deleted.

294 The volume of trauma admissions with ISS >15 (<240 vs > or =240 cases per year) had no effect

295 ma (<240 vs > or =240 trauma admissions with ISS >15 per year).

296 ult height in pre and peripubertal boys with ISS when re-assessed 4 years after the treatment period.

297 g WBCT due to trauma, multiple injuries with ISS > 15 were found in 74 individuals (24.4%).

298 However, incubation of MBMMCs with ISS in vitro neither inhibited MBMMC proliferation nor i

299 repetitive OVA challenges, were treated with ISS for 1-3 mo.

300 n 30- to 1,080-d missions, without and with, ISS-like CM exercise (modelled as 2 x 30-min aerobic exe